← Leaderboards
Frank Sciavolino
Thetis Pharmaceuticals, Llc
$7,024,050
Attributed
$7,024,050
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.5M · FY2017–21$2.5M$1.9M$1.3M$625K$0
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$7,024,050 · 5
By mechanism
R44$6,730,328 · 4
R43$293,722 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Affect”
- Chanza Baytop · Westat, Inc.$271,217,917
- Leonard Freedman · Leidos Biomedical Research, Inc.$62,378,387
- Jennifer Marie Suga · Kaiser Foundation Research Institute$29,218,159
- Lynn Briscoe · Leidos Biomedical Research, Inc.$27,788,199
- George Robert Painter · University Of Alabama At Birmingham$27,619,145
- Jessica Brooke Langbaum · Banner Health$22,633,312
Research focus
AffectSmall Business Innovation Research GrantToxicologyInnovationSafetyDoseInflammationPharmaceutical PreparationsBasePharmacologic SubstanceMedicalOmega-3 Fatty AcidsChronicOralFutureTabletsClinical ResearchClinical DevelopmentMediator Of Activation ProteinSymptomsEicosapentaenoic AcidFormulationDrug KineticsResolution
Grant awards (11)
Development of a Novel Resolvin-Based Therapy for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS)$299,561
R44 · FY2021 · AI · contact PI
Development of TP-352 for the Treatment of Pediatric Non-alcoholic Steatohepatitis$1,982,861
R44 · FY2020 · DK · contact PI
Development of TP-252 for the Maintenance of Remission in Pediatric Ulcerative Colitis Patients$498,366
R44 · FY2020 · DK · contact PI
Development of TP-252 for the Maintenance of Remission in Pediatric Ulcerative Colitis Patients$1,196,452
R44 · FY2019 · DK · contact PI
Development of TP-317 for the Induction and Maintenance of Remission in Ulcerative Colitis Patients$571,983
R44 · FY2019 · DK · contact PI
Development of TP-352 for the Treatment of Pediatric Non-alcoholic Steatohepatitis$295,609
R44 · FY2019 · DK · contact PI
Development of TP-317 for the Treatment of Eosinophilic Esophagitis$293,722
R43 · FY2019 · AI · contact PI
Development of TP-317 for the Induction and Maintenance of Remission in Ulcerative Colitis Patients$1,396,059
R44 · FY2018 · DK · contact PI
Development of TP-252 for the Maintenance of Remission in Pediatric Ulcerative Colitis Patients$205,144
R44 · FY2018 · DK · contact PI
Development of TP-317 for the Induction and Maintenance of Remission in Ulcerative Colitis Patients$78,301
R44 · FY2018 · DK · contact PI
Development of TP-317 for the Induction and Maintenance of Remission in Ulcerative Colitis Patients$205,992
R44 · FY2017 · DK · contact PI